Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Immune Checkpoint Inhibitor–Based Therapy for Early-Stage Lung Cancer: Medical Oncology Perspective
  • CME
  • CE

person default
Patrick Forde, MB BCh
Released: August 26, 2021
Back Next

References

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. v.5.2021. nccn.org. Accessed August 23, 2021.
  2. Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198:897-907.
  3. Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017;151:193-203.
  4. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol. 2016;11:39-51.
  5. Neppl C, Keller MD, Scherz A, et al. Comparison of the 7th and 8th Edition of the UICC/AJCC TNM staging system in primary resected squamous cell carcinomas of the lung—a single center analysis of 354 cases. Front Med (Lausanne). 2019;6:196.
  6. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
  7. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711-1723.
  8. Osimertinib [prescribing information]. Waltham, MA: AstraZeneca Pharmaceuticals LP; 2021.
  9. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892-2911.
  10. Lewis J, Gillaspie EA, Osmundson EC, et al. Before or after: evolving neoadjuvant approaches to locally advanced non-small cell lung cancer. Front Oncol. 2018;8:5.
  11. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28:3138-3145.
  12. Hellman MD. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42-e50.
  13. McElnay P, Lim E. Adjuvant or neoadjuvant chemotherapy for NSCLC. J Thorac Dis. 2014;6(suppl 2):S224-S227.
  14. Yuan M, Huang LL, Chen JH, et al. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.
  15. Forde PM, Spicer J, Lu S, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Presented at: 2021 American Association for Cancer Research Annual Meeting; April 10-15 and May 17-21, 2021. Abstract CT003.
  16. Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29:1853-1860.
  17. Baden J, Chang H, Greeenawalt DM, et al. Comparison of platforms for determining tumor mutational burden (TMB) from blood samples in patients with non-small cell lung cancer (NSCLC). Presented at: 2019 European Society for Medical Oncology Congress; September 27 - October 1, 2019. Abstract 2736.
  18. ClinicalTrials.gov. Efficacy and safety of pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant/adjuvant therapy for participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (MK-3475-671/KEYNOTE-671). clinicaltrials.gov/ct2/show/NCT03425643. Accessed August 23, 2021.
  19. ClinicalTrials.gov. A study of neoadjuvant atezolizumab plus chemotherapy versus placebo plus chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer (IMpower030). clinicaltrials.gov/ct2/show/NCT03456063. Accessed August 23, 2021.
  20. ClinicalTrials.gov. A study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable non-small cell lung cancer (AEGEAN). clinicaltrials.gov/ct2/show/NCT03800134. Accessed August 23, 2021.
  21. ClinicalTrials.gov. A study of neoadjuvant chemotherapy plus nivolumab versus neoadjuvant chemotherapy plus placebo, followed by surgical removal and adjuvant treatment with nivolumab or placebo for participants with surgically removable early stage non-small-cell lung cancer. clinicaltrials.gov/ct2/show/NCT04025879. Accessed August 23, 2021.
  22. Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8500.
  23. US Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. fda.gov/media/71195/download. Accessed August 23, 2021.
  24. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;282:41-50.
  25. Topalian SL, Hodi FS, Brahmer JR. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5:1411-1420.
  26. ClinicalTrials.gov. Study to assess safety and efficacy of atezolizumab (MPDL3280A) compared to best supportive care following chemotherapy in patients with lung cancer [IMpower010]. clinicaltrials.gov/ct2/show/NCT02486718. Accessed August 23, 2021.
  27. ClinicalTrials.gov. Nivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer (an ALCHEMIST treatment trial) (ANVIL). clinicaltrials.gov/ct2/show/NCT02595944. Accessed August 23, 2021.
  28. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) vs placebo for participants with non-small cell lung cancer after resection with or without standard adjuvant therapy (MK-3475-091/KEYNOTE-091) (PEARLS). clinicaltrials.gov/ct2/show/NCT02504372. Accessed August 23, 2021.
  29. ClinicalTrials.gov. Double blind placebo controlled study of adjuvant MEDI4736 in completely resected NSCLC. clinicaltrials.gov/ct2/show/NCT02273375. Accessed August 23, 2021.
  30. ClinicalTrials.gov. Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO (ACCIO). clinicaltrials.gov/ct2/show/NCT04267848. Accessed August 23, 2021.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings